Common TitleETOILE
Official Title Study of the Immunological Efficacy of Adding Subcutaneous Interleukin-2 (IL-2) to an Optimized Antiretroviral Regimen in HIV-1-infected Subjects Experiencing Therapeutic Failure on an Ongoing Antiretroviral Combination With a CD4 Cell Count ≤ 200/mm3 ANRS 123 Trial
Phase Phase II
ClinicalTrials.gov NCT00113282
Treatments
Enfuvirtide
Enfuvirtide
Tradename:FuzeonOther Names:T-20Class:Entry InhibitorsCategories Resistance/Virological FailureTreatment-Experienced
Funding
Non-IndustryFrench National Agency for Research on AIDS and Viral Hepatitis
References
- Viard JP, Fagard C, Chaix ML, et al. Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients. AIDS. 2009;23:1383-8.